Biology:Fotagliptin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | SAL067 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H19FN6O |
| Molar mass | 342.378 g·mol−1 |
Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP.[1][2][3] In a phase 3 trial it showed similar results as alogliptin.[4]
References
- ↑ Wu, Min; Li, Qian‐Qian; Zhang, Hong; Zhu, Xiao‐Xue; Li, Xiao‐Jiao; Li, Ying; Sun, Hai‐Gang; Ding, Yan‐Hua (June 2021). "Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus" (in en). Clinical Pharmacology in Drug Development 10 (6): 660–668. doi:10.1002/cpdd.895. ISSN 2160-763X. PMID 33440080. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/cpdd.895.
- ↑ Fang, Lan; Gao, Zhenguo; Wu, Songgu; Jia, Shengzhe; Wang, Jingkang; Rohani, Sohrab; Gong, Junbo (1 August 2021). "Ultrasound-assisted solution crystallization of fotagliptin benzoate: Process intensification and crystal product optimization". Ultrasonics Sonochemistry 76: 105634. doi:10.1016/j.ultsonch.2021.105634. ISSN 1350-4177. PMID 34218067.
- ↑ Ding, Yanhua; Zhang, Hong; Li, Cuiyun; Zheng, WenBo; Wang, Meng; Li, Ying; Sun, HaiGang; Wu, Min (3 June 2021). "Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology 17 (6): 725–731. doi:10.1080/17425255.2021.1915283. PMID 33899649.
- ↑ Xu, Mingtong; Sun, Kan; Xu, Wenjie; Wang, Chuan; Yan, Dewen; Li, Shu; Cong, Li; Pi, Yinzhen et al. (2023). "Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial". BMC Medicine 21 (1): 388. doi:10.1186/s12916-023-03089-x. ISSN 1741-7015. PMID 37814306.
 |  |
